scholarly article | Q13442814 |
P50 | author | Orestis Efthimiou | Q56425988 |
P2093 | author name string | Ian R White | |
P2860 | cites work | The BUGS project: Evolution, critique and future directions | Q28252857 |
Meta-assessment of bias in science | Q29032830 | ||
What's wrong with Bonferroni adjustments | Q29615550 | ||
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. | Q30240984 | ||
Efficacy of new generation antidepressants: differences seem illusory | Q34765596 | ||
Evaluation of networks of randomized trials | Q36966424 | ||
Use of network meta-analysis in clinical guidelines | Q37298550 | ||
Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension | Q37897512 | ||
A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo | Q37948619 | ||
Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis | Q38283269 | ||
Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. | Q38321131 | ||
Characteristics of networks of interventions: a description of a database of 186 published networks | Q39263369 | ||
Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 | ||
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 | ||
Network meta-analysis models to account for variability in treatment definitions: application to dose effects | Q45812519 | ||
Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes | Q46534048 | ||
Multiple hypothesis testing in genomics. | Q46937467 | ||
Network meta-analyses should be the highest level of evidence in treatment guidelines. | Q47978770 | ||
Linear inference for mixed treatment comparison meta-analysis: A two-stage approach | Q51599066 | ||
Borrowing strength from external trials in a meta-analysis | Q52287071 | ||
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool | Q57542870 | ||
Network meta-analysis: the highest level of medical evidence? | Q60628651 | ||
Scientists rise up against statistical significance | Q66778032 | ||
Random main effects of treatment: A case study with a network meta-analysis | Q90955167 | ||
Incorporating external evidence on between-trial heterogeneity in network meta-analysis | Q93386504 | ||
P433 | issue | 1 | |
P304 | page(s) | 105-122 | |
P577 | publication date | 2019-10-14 | |
P1433 | published in | Research Synthesis Methods | Q26842395 |
P1476 | title | The dark side of the force: Multiplicity issues in network meta-analysis and how to address them | |
P478 | volume | 11 |
Q92149111 | Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis | cites work | P2860 |
Search more.